Medtronic will market Neurex' neuron specific calcium channel blocker/non-opioid analgesic ziconotide in the U.S., Elan tells Nationsbanc Montgomery Securities Healthcare conference July 16. Medtronic developed the intrathecal pump that will be used with the drug. Newly-acquired Elan subsidiary Neurex will receive 45% of sales revenues. Neurex expects to file a ziconotide NDA for chronic neuropathic/malignant pain in the fourth quarter
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth